Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol with Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol

Not yet recruiting

• Conditions: Stimulation in the Ovary; IVF Outcome

• Registration Number: NCT06879002
• Lead Sponsor: ART Fertility Clinics LLC

Brief Summary

There are several approaches to the timing of antagonist administration in IVF/ICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs /burden without having an impact on the outcome.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-03
• Study First Submitted: 2025-03-11
• Study First Submitted QC: 2025-03-11
• Study First Posted: 2025-03-17
• Last Update Submitted: 2025-03-17
• Last Update Posted: 2025-03-19
• Study Start: 2025-04-30
• Primary Completion: 2026-04-30
• Study Completion: 2026-12-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 252

Inclusion Criteria

• Age 18 to 38 years old.
• Normal Menstrual cycle of 25-35 days.
• Body Weight 60to90 kg
• AMH>1.3 - <3 ng/m (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) an antral follicle count (AFC) of >5 on menstrual cycle days 2-3,

Exclusion Criteria

• History of premature ovulation
• Azoospermia
• PCOS
• Endometriosis AFS ¾
• Endometrioma
• Known chromosomal abnormalities

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate the Oocyte maturity, Fertilization rate, Blastulation rate, quality Euploidy rate, Premature ovulation rate, Number of injections used and costs	From enrollment to the end of treatment at 8 weeks

Trial Locations

Locations (2)

ART Fertility Clinics LLC; 🇦🇪 Abu Dhabi, United Arab Emirates

ART Fertility Clinics LLC - Dubai; 🇦🇪 Dubai, United Arab Emirates